Screener
Citius Oncology, Inc. CTOR Ratios & Valuation
| Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -126.6%-19.0pp | -119.9%-26.3pp | -47.4%+24.7pp | -54.4%+4.6pp | -107.5%— | |
| Liquidity | ||||||
| Current ratio | 0.7×+0.4× | 0.5×+0.1× | 0.8×+0.4× | 0.6×+0.2× | 0.3×+0.3× | |
| Leverage | ||||||
| Debt-to-equity | 0.4×— | —— | —— | —— | —— | |
| Per Share | ||||||
| Book value per share | $0.37-17.3% | $0.35-29.2% | $0.67+15.7% | $0.61-9.7% | $0.45+79.5% | |
| Valuation | ||||||
| Market capitalization | $83.24M-49.2% | $54.72M-17.8% | $84.8M+3.1% | $169.53M— | $190.33M— | |
| Price / book | 2.1×-3.0× | 1.6×-0.3× | 1.5×-0.5× | 3.8×— | 5.9×— |
FAQ
- Where do Citius Oncology, Inc.'s ratios come from?
- Every ratio is computed from Citius Oncology, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.